Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 17 | 2023 | 2998 | 2.620 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 2 | 2022 | 428 | 0.770 |
Why?
|
| Lung Diseases, Interstitial | 3 | 2022 | 778 | 0.760 |
Why?
|
| Heparin | 3 | 2021 | 1620 | 0.640 |
Why?
|
| Genetic Markers | 2 | 2022 | 2688 | 0.550 |
Why?
|
| Pulmonary Emphysema | 1 | 2020 | 676 | 0.540 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2023 | 17409 | 0.440 |
Why?
|
| Venous Thromboembolism | 2 | 2021 | 1582 | 0.440 |
Why?
|
| Lung | 10 | 2023 | 9739 | 0.410 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 1216 | 0.410 |
Why?
|
| Intensive Care Units | 2 | 2021 | 3451 | 0.390 |
Why?
|
| Genome-Wide Association Study | 7 | 2023 | 11940 | 0.350 |
Why?
|
| Spirometry | 5 | 2022 | 876 | 0.340 |
Why?
|
| Hypertension, Pulmonary | 4 | 2021 | 1512 | 0.320 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 2361 | 0.320 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2023 | 15603 | 0.290 |
Why?
|
| Disease Progression | 2 | 2022 | 13215 | 0.280 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3163 | 0.270 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3280 | 0.270 |
Why?
|
| Multifactorial Inheritance | 2 | 2022 | 1153 | 0.260 |
Why?
|
| Respiratory Function Tests | 4 | 2022 | 1678 | 0.250 |
Why?
|
| Antihypertensive Agents | 3 | 2020 | 2058 | 0.240 |
Why?
|
| Phenotype | 7 | 2022 | 16311 | 0.230 |
Why?
|
| Anticoagulants | 4 | 2021 | 4375 | 0.230 |
Why?
|
| Respiratory System Abnormalities | 1 | 2022 | 68 | 0.210 |
Why?
|
| Pulmonary Artery | 2 | 2020 | 1894 | 0.210 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2022 | 170 | 0.200 |
Why?
|
| Vital Capacity | 2 | 2021 | 927 | 0.200 |
Why?
|
| Risk Assessment | 2 | 2022 | 23476 | 0.200 |
Why?
|
| Drug Repositioning | 1 | 2023 | 215 | 0.200 |
Why?
|
| Mitochondria, Liver | 1 | 2021 | 223 | 0.200 |
Why?
|
| Acetyltransferases | 1 | 2021 | 238 | 0.200 |
Why?
|
| Prothrombin Time | 1 | 2020 | 123 | 0.190 |
Why?
|
| Partial Thromboplastin Time | 1 | 2020 | 209 | 0.190 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2021 | 128 | 0.180 |
Why?
|
| Epoprostenol | 1 | 2020 | 279 | 0.180 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2020 | 438 | 0.180 |
Why?
|
| Risk Factors | 10 | 2022 | 70879 | 0.180 |
Why?
|
| Forced Expiratory Volume | 2 | 2021 | 1750 | 0.170 |
Why?
|
| Humans | 40 | 2023 | 715818 | 0.170 |
Why?
|
| Enoxaparin | 1 | 2020 | 364 | 0.170 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 443 | 0.160 |
Why?
|
| Ferritins | 1 | 2020 | 581 | 0.160 |
Why?
|
| Internationality | 1 | 2022 | 997 | 0.150 |
Why?
|
| Fibrinogen | 1 | 2020 | 919 | 0.150 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2022 | 3645 | 0.150 |
Why?
|
| Sebaceous Glands | 1 | 2016 | 47 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2022 | 15911 | 0.140 |
Why?
|
| Meta-Analysis as Topic | 1 | 2021 | 1373 | 0.140 |
Why?
|
| Middle Aged | 14 | 2022 | 214666 | 0.140 |
Why?
|
| Blood Coagulation | 1 | 2021 | 1110 | 0.140 |
Why?
|
| Interleukin-10 | 1 | 2020 | 1203 | 0.130 |
Why?
|
| Heterozygote | 1 | 2022 | 2794 | 0.130 |
Why?
|
| Acetamides | 1 | 2016 | 252 | 0.130 |
Why?
|
| Sarcoidosis | 1 | 2020 | 524 | 0.130 |
Why?
|
| Odds Ratio | 3 | 2022 | 9985 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2022 | 15198 | 0.130 |
Why?
|
| rho-Associated Kinases | 1 | 2016 | 288 | 0.130 |
Why?
|
| Pandemics | 4 | 2022 | 7313 | 0.130 |
Why?
|
| Propensity Score | 1 | 2021 | 1762 | 0.130 |
Why?
|
| Amides | 1 | 2016 | 449 | 0.120 |
Why?
|
| Hypersensitivity, Immediate | 1 | 2016 | 334 | 0.120 |
Why?
|
| Drugs, Investigational | 1 | 2015 | 234 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2022 | 12305 | 0.110 |
Why?
|
| Models, Genetic | 1 | 2022 | 3516 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2020 | 3171 | 0.100 |
Why?
|
| Pyrazines | 1 | 2016 | 1246 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2022 | 20357 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2020 | 1373 | 0.100 |
Why?
|
| Cohort Studies | 3 | 2022 | 40032 | 0.100 |
Why?
|
| Asthma | 2 | 2021 | 5945 | 0.100 |
Why?
|
| Genetic Variation | 2 | 2022 | 6664 | 0.090 |
Why?
|
| Male | 15 | 2022 | 350352 | 0.090 |
Why?
|
| Alcohol Drinking | 1 | 2022 | 3899 | 0.090 |
Why?
|
| Female | 16 | 2022 | 377229 | 0.090 |
Why?
|
| Cause of Death | 1 | 2020 | 3612 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2020 | 3713 | 0.080 |
Why?
|
| Critical Care | 1 | 2021 | 2494 | 0.080 |
Why?
|
| Critical Illness | 1 | 2021 | 2529 | 0.080 |
Why?
|
| Plastids | 1 | 2007 | 9 | 0.080 |
Why?
|
| Postprandial Period | 1 | 2009 | 306 | 0.080 |
Why?
|
| Seeds | 1 | 2007 | 102 | 0.080 |
Why?
|
| Genotype | 1 | 2022 | 12919 | 0.080 |
Why?
|
| Pneumonia | 1 | 2018 | 2099 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2020 | 5922 | 0.080 |
Why?
|
| Aged | 8 | 2022 | 162468 | 0.080 |
Why?
|
| Plant Oils | 1 | 2007 | 190 | 0.070 |
Why?
|
| Adult | 10 | 2022 | 212279 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2022 | 21795 | 0.070 |
Why?
|
| Pyruvate Kinase | 1 | 2007 | 187 | 0.070 |
Why?
|
| African Americans | 1 | 2020 | 5003 | 0.070 |
Why?
|
| Incidence | 2 | 2020 | 20733 | 0.070 |
Why?
|
| Pyridines | 1 | 2016 | 2846 | 0.060 |
Why?
|
| Arabidopsis | 1 | 2007 | 462 | 0.060 |
Why?
|
| Sequence Analysis, RNA | 2 | 2022 | 2016 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2022 | 51317 | 0.060 |
Why?
|
| Genetic Loci | 2 | 2022 | 2615 | 0.060 |
Why?
|
| Mucin-5B | 1 | 2022 | 137 | 0.050 |
Why?
|
| Genes, Overlapping | 1 | 2021 | 37 | 0.050 |
Why?
|
| Transcription Factors | 1 | 2022 | 11953 | 0.050 |
Why?
|
| Logistic Models | 3 | 2022 | 13623 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 200 | 0.050 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2022 | 310 | 0.050 |
Why?
|
| Triglycerides | 1 | 2009 | 2577 | 0.050 |
Why?
|
| Linear Models | 2 | 2021 | 5984 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 4913 | 0.050 |
Why?
|
| Molecular Epidemiology | 1 | 2022 | 483 | 0.050 |
Why?
|
| Sample Size | 1 | 2022 | 823 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2020 | 62040 | 0.040 |
Why?
|
| Cardiac Output | 1 | 2020 | 905 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 2020 | 949 | 0.040 |
Why?
|
| Child | 2 | 2022 | 74468 | 0.040 |
Why?
|
| Biological Specimen Banks | 1 | 2021 | 647 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 23437 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 1525 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2021 | 72473 | 0.040 |
Why?
|
| Europe | 1 | 2022 | 3343 | 0.040 |
Why?
|
| Smoking | 2 | 2023 | 8980 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 12540 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2009 | 6539 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2016 | 963 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 2015 | 603 | 0.030 |
Why?
|
| Monocytes | 1 | 2022 | 2620 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 2720 | 0.030 |
Why?
|
| Aged, 80 and over | 3 | 2022 | 58326 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 1402 | 0.030 |
Why?
|
| Eosinophils | 1 | 2016 | 936 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2022 | 6009 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2021 | 4214 | 0.020 |
Why?
|
| Drug Design | 1 | 2015 | 1099 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 2016 | 1496 | 0.020 |
Why?
|
| Cell Proliferation | 2 | 2016 | 10615 | 0.020 |
Why?
|
| United States | 3 | 2022 | 67910 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2022 | 6105 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2016 | 3955 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2022 | 10503 | 0.020 |
Why?
|
| Time Factors | 2 | 2020 | 40887 | 0.020 |
Why?
|
| Cotyledon | 1 | 2007 | 4 | 0.020 |
Why?
|
| Gene Expression | 1 | 2021 | 7954 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 12460 | 0.020 |
Why?
|
| Genes, Plant | 1 | 2007 | 127 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 4193 | 0.020 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2007 | 202 | 0.020 |
Why?
|
| Vitamin D | 1 | 2020 | 3193 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 12483 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 13643 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2020 | 9034 | 0.020 |
Why?
|
| Carbon | 1 | 2007 | 656 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 2824 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2007 | 2086 | 0.020 |
Why?
|
| Multienzyme Complexes | 1 | 2007 | 701 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2007 | 1001 | 0.010 |
Why?
|
| Glycolysis | 1 | 2007 | 810 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2007 | 1831 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 4379 | 0.010 |
Why?
|
| Brain | 1 | 2009 | 25208 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2007 | 1534 | 0.010 |
Why?
|
| Animals | 3 | 2022 | 169404 | 0.010 |
Why?
|
| Adolescent | 2 | 2022 | 85157 | 0.010 |
Why?
|
| Protein Transport | 1 | 2007 | 2054 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2009 | 2048 | 0.010 |
Why?
|
| Prognosis | 1 | 2020 | 29007 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 9504 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 11722 | 0.010 |
Why?
|
| Kinetics | 1 | 2007 | 6654 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 9596 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 2744 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2007 | 1990 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 6803 | 0.010 |
Why?
|
| Inflammation | 1 | 2015 | 10082 | 0.010 |
Why?
|
| Young Adult | 1 | 2022 | 56228 | 0.010 |
Why?
|
| Mice | 1 | 2022 | 80373 | 0.010 |
Why?
|
| Protein Binding | 1 | 2007 | 9558 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2015 | 23729 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 9004 | 0.010 |
Why?
|
| Mutation | 1 | 2007 | 29290 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 34430 | 0.000 |
Why?
|
Concepts
(177)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(91)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_